Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubicin vs Lomustine in Recurrent Glioblastoma Multiforme
NCT04762069Phase 2Active, not recruiting
- Sponsor
- CNS Pharmaceuticals
- Start
- May 2021
- Primary completion
- Apr 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
A Phase 2 trial of berubicin in glioblastoma multiforme (GBM), sponsored by CNS Pharmaceuticals. Started May 2021; status: active, not recruiting.
02
Drugs
berubicin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04762069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762069.